Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2048177 | 0.91 | GRM4 (0.42) | ALDH1A1MAPTSMN1; SMN2HSD11B1ATM | |
| SCHEMBL3828109 | 0.91 | GRM4 (0.42) | ALDH1A1MAPTSMN1; SMN2HSD11B1ATM | |
| SCHEMBL4674416 | 0.91 | GRM4 (0.42) | ALDH1A1MAPTSMN1; SMN2HSD11B1ATM | |
| SCHEMBL2048228 | 0.91 | GRM4 (0.42) | ALDH1A1MAPTSMN1; SMN2HSD11B1ATM | |
| SCHEMBL4601079 | 0.84 | KMT2A (0.50) | ALDH1A1MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL14220686 | 0.84 | KMT2A (0.50) | ALDH1A1MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4601395 | 0.84 | TSHR (0.45) | ALDH1A1SMN1; SMN2ESR2HPGDKMT2A | |
| SCHEMBL4600107 | 0.83 | HTR2C (0.54) | ALDH1A1DRD2LMNAHPGDKMT2A | |
| SCHEMBL4601341 | 0.83 | ESR2 (0.45) | ALDH1A1SMN1; SMN2DRD2L3MBTL1ESR2 | |
| SCHEMBL14117545 | 0.82 | ESR2 (0.56) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022197-A1 | METHODS OF REVERSING TICAGRELOR ACTIVITY | SFJ PHARMA X INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025129010-A1 | METHODS OF STRUCTURE DETERMINATION USING ANTIBODIES | GENENTECH, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240350653-A1 | TARGETED DELIVERY OF THERAPEUTIC ENZYMES | JOINT STOCK COMPANY GENERIUM (RU) | 2024-10-24 | — | — | US | disclosed |
| WO-2024177535-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE PROPHYLAXIS AND TREATMENT OF A LYSOSOMAL ENZYME DEFICIENCY IN A SUBJECT WITH MUCOPOLYSACCHARIDOSIS TYPE II | Акционерное общество "ГЕНЕРИУМ" | 2024-08-29 | — | — | WO | disclosed |
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4389772-A1 | TARGETED DELIVERY OF THERAPEUTIC ENZYMES | Joint-Stock Company "Generium" (RU) | 2024-06-26 | — | — | EP | disclosed |
| CN-118019768-A | Targeted delivery of therapeutic enzymes | 吉尼瑞姆股份公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023022629-A1 | TARGETED DELIVERY OF THERAPEUTIC ENZYMES | Акционерное общество "ГЕНЕРИУМ" | 2023-02-23 | — | — | WO | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3960768-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | F. Hoffmann-La Roche AG (CH) | 2022-03-02 | — | — | EP | disclosed |
| US-7045591-B2 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI | 2005-10-27 | — | — | US | disclosed |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2003-12-11 | — | — | US | disclosed |
| US-6600015-B2 | Treatment or prevention of obesity. | HOFFMANN-LA ROCHE INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1315750-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1272516-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2002018437-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001074844-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ALDH1A1 4570/4885MAPT 4043/4885SMN1; SMN2 3076/4885 |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ALDH1A1 4730/4885MAPT 3165/4885SMN1; SMN2 2900/4885 |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | MC4R, MC1R, MC3R | ALDH1A1 4691/4885MAPT 3560/4885SMN1; SMN2 3821/4885 |
| US-20260022197-A1 | METHODS OF REVERSING TICAGRELOR ACTIVITY | P2RY12, P2RY13, PTAFR | ALDH1A1 1592/4885MAPT 2579/4885SMN1; SMN2 914/4885 |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | ALDH1A1 4684/4885MAPT 3168/4885SMN1; SMN2 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.